Data as of Nov 26
| -0.07 / -0.46%|
The 5 analysts offering 12-month price forecasts for Theravance Inc have a median target of 18.00, with a high estimate of 47.00 and a low estimate of 7.00. The median estimate represents a +18.03% increase from the last price of 15.25.
The current consensus among 7 polled investment analysts is to Hold stock in Theravance Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.